149 related articles for article (PubMed ID: 36289628)
1. Serum CCL2 Is a Prognostic Biomarker for Non-Metastatic Castration-Sensitive Prostate Cancer.
Iwamoto H; Izumi K; Nakagawa R; Toriumi R; Aoyama S; Kamijima T; Shimada T; Kano H; Makino T; Naito R; Kadomoto S; Yaegashi H; Kawaguchi S; Nohara T; Shigehara K; Kadono Y; Mizokami A
Biomedicines; 2022 Sep; 10(10):. PubMed ID: 36289628
[TBL] [Abstract][Full Text] [Related]
2. Usefulness of serum CCL2 as prognostic biomarker in prostate cancer: a long-term follow-up study.
Iwamoto H; Izumi K; Nakagawa R; Toriumi R; Aoyama S; Shimada T; Kano H; Makino T; Kadomoto S; Yaegashi H; Kawaguchi S; Nohara T; Shigehara K; Kadono Y; Mizokami A
Jpn J Clin Oncol; 2022 Nov; 52(11):1337-1344. PubMed ID: 35726158
[TBL] [Abstract][Full Text] [Related]
3. Serum chemokine (CC motif) ligand 2 level as a diagnostic, predictive, and prognostic biomarker for prostate cancer.
Izumi K; Mizokami A; Lin HP; Ho HM; Iwamoto H; Maolake A; Natsagdorj A; Kitagawa Y; Kadono Y; Miyamoto H; Huang CK; Namiki M; Lin WJ
Oncotarget; 2016 Feb; 7(7):8389-98. PubMed ID: 26701731
[TBL] [Abstract][Full Text] [Related]
4. Time to castration-resistant prostate cancer and prostate cancer death according to PSA response in men with non-metastatic prostate cancer treated with gonadotropin releasing hormone agonists.
Bonde TM; Westerberg M; Aly M; Eklund M; Adolfsson J; Bill-Axelson A; Garmo H; Stattin P; Robinson D
Scand J Urol; 2022 Jun; 56(3):169-175. PubMed ID: 35548951
[No Abstract] [Full Text] [Related]
5. [CLINICAL STUDY OF THE PROSTATE CANCERS WITH A SERUM PROSTATE SPECIFIC ANTIGEN LEVEL OF MORE THAN 100 ng/ml AT THE FIRST DIAGNOSIS].
Chikazawa I; Kunii K; Ushimoto C; Inoue S; Nakazawa Y; Fukuda Y; Suga K; Morita N; Tanaka T; Miyazawa K
Nihon Hinyokika Gakkai Zasshi; 2019; 110(3):168-176. PubMed ID: 32684577
[TBL] [Abstract][Full Text] [Related]
6. Is there any prognostic impact of intraductal carcinoma of prostate in initial diagnosed aggressively metastatic prostate cancer?
Zhao T; Liao B; Yao J; Liu J; Huang R; Shen P; Peng Z; Gui H; Chen X; Zhang P; Zhu Y; Li X; Wei Q; Zhou Q; Zeng H; Chen N
Prostate; 2015 Feb; 75(3):225-32. PubMed ID: 25307858
[TBL] [Abstract][Full Text] [Related]
7. Alkaline phosphatase velocity predicts overall survival and bone metastasis in patients with castration-resistant prostate cancer.
Hammerich KH; Donahue TF; Rosner IL; Cullen J; Kuo HC; Hurwitz L; Chen Y; Bernstein M; Coleman J; Danila DC; Metwalli AR
Urol Oncol; 2017 Jul; 35(7):460.e21-460.e28. PubMed ID: 28410987
[TBL] [Abstract][Full Text] [Related]
8. Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer.
Pienta KJ; Machiels JP; Schrijvers D; Alekseev B; Shkolnik M; Crabb SJ; Li S; Seetharam S; Puchalski TA; Takimoto C; Elsayed Y; Dawkins F; de Bono JS
Invest New Drugs; 2013 Jun; 31(3):760-8. PubMed ID: 22907596
[TBL] [Abstract][Full Text] [Related]
9. Clinical Characterization of Low Prostate-specific Antigen on Prognosis in Patients With Metastatic Castration-naive Prostate Cancer.
Kodama H; Hatakeyama S; Narita S; Takahashi M; Sakurai T; Kawamura S; Hoshi S; Ishida M; Kawaguchi T; Ishidoya S; Shimoda J; Narita T; Sato H; Mitsuzuka K; Tochigi T; Tsuchiya N; Arai Y; Habuchi T; Ohyama C
Clin Genitourin Cancer; 2019 Dec; 17(6):e1091-e1098. PubMed ID: 31575477
[TBL] [Abstract][Full Text] [Related]
10. The Role of Fast and Deep PSA Response in Castration-sensitive Prostate Cancer.
Iacovelli R; Ciccarese C; Caffo O; De Giorgi U; Basso U; Tucci M; Mosillo C; Maruzzo M; Maines F; Casadei C; Milella M; Tortora G
Anticancer Res; 2022 Jan; 42(1):165-172. PubMed ID: 34969722
[TBL] [Abstract][Full Text] [Related]
11. Pretreatment neutrophil-to-lymphocyte ratio as a potential prognostic biomarker for newly diagnosed patients with metastatic castration-sensitive prostate cancer.
Salah S; Abu-Hijlih R; Abuhijla F; Tamimi F; Al-Tell A; Shahait M
Cancer Rep (Hoboken); 2021 Oct; 4(5):e1392. PubMed ID: 34159754
[TBL] [Abstract][Full Text] [Related]
12. A phase 3 randomised study of enzalutamide plus leuprolide and enzalutamide monotherapy in high-risk non-metastatic hormone-sensitive prostate cancer with rising PSA after local therapy: EMBARK study design.
Freedland SJ; De Giorgi U; Gleave M; Rosbrook B; Shen Q; Sugg J; Haas GP; Shore ND
BMJ Open; 2021 Aug; 11(8):e046588. PubMed ID: 34385241
[TBL] [Abstract][Full Text] [Related]
13. Elevated alkaline phosphatase velocity strongly predicts overall survival and the risk of bone metastases in castrate-resistant prostate cancer.
Metwalli AR; Rosner IL; Cullen J; Chen Y; Brand T; Brassell SA; Lesperance J; Porter C; Sterbis J; McLeod DG
Urol Oncol; 2014 Aug; 32(6):761-8. PubMed ID: 24929891
[TBL] [Abstract][Full Text] [Related]
14. Survival in patients diagnosed with castration-resistant prostate cancer: a population-based observational study in Sweden.
Aly M; Leval A; Schain F; Liwing J; Lawson J; Vágó E; Nordström T; Andersson TM; Sjöland E; Wang C; Eloranta S; Akre O
Scand J Urol; 2020 Apr; 54(2):115-121. PubMed ID: 32266854
[No Abstract] [Full Text] [Related]
15. [The subgroup analysis of the prognostic value of the intraductal carcinoma of the prostate in patients with metastatic prostate cancer].
Zhao JG; Nie L; Chen XQ; Chen N; Zeng H
Zhonghua Wai Ke Za Zhi; 2019 Jun; 57(6):422-427. PubMed ID: 31142066
[No Abstract] [Full Text] [Related]
16. Serum alkaline phosphatase differentiates prostate-specific antigen flare from early disease progression after docetaxel chemotherapy in castration-resistant prostate cancer with bone metastasis.
Han KS; Hong SJ
J Cancer Res Clin Oncol; 2014 Oct; 140(10):1769-76. PubMed ID: 24858569
[TBL] [Abstract][Full Text] [Related]
17. In Men with Castration-Resistant Prostate Cancer, Visceral Metastases Predict Shorter Overall Survival: What Predicts Visceral Metastases? Results from the SEARCH Database.
Whitney CA; Howard LE; Posadas EM; Amling CL; Aronson WJ; Cooperberg MR; Kane CJ; Terris MK; Freedland SJ
Eur Urol Focus; 2017 Oct; 3(4-5):480-486. PubMed ID: 28753787
[TBL] [Abstract][Full Text] [Related]
18. Predictors of poor response to first-generation anti-androgens as criteria for alternate treatments for patients with non-metastatic castration-resistant prostate cancer.
Fukuoka K; Teishima J; Nagamatsu H; Inoue S; Hayashi T; Mita K; Shigeta M; Kobayashi K; Kajiwara M; Kadonishi Y; Tacho T; Matsubara A
Int Urol Nephrol; 2020 Jan; 52(1):77-85. PubMed ID: 31552574
[TBL] [Abstract][Full Text] [Related]
19. Plasma Chemokine C-C Motif Ligand 2 as a Potential Biomarker for Prostate Cancer.
Lund M; Pedersen TB; Feddersen S; Østergaard LD; Poulsen CA; Enggaard C; Poulsen MHA; Lund L
Res Rep Urol; 2022; 14():33-38. PubMed ID: 35178362
[TBL] [Abstract][Full Text] [Related]
20. Prostate-specific antigen kinetic profiles during androgen deprivation therapy as prognostic factors in castration-resistant prostate cancer.
Kim M; Lee J; Jeong CW; Ku JH; Kim HH; Kwak C
Urol Oncol; 2015 May; 33(5):203.e1-9. PubMed ID: 25726498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
